河 河北常山生化药 药业股份有限公 司 2025 年半年度报告全文 河北常山生化 化药业股 股份有限 限公司 2025 年 年半年度 度报告 2025-36 202 25 年 8 月 月 1 河北常山生化药业股份有限公司 2025 年半年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人高晓东、主管会计工作负责人岳晓华及会计机构负责人(会计 主管人员)岳晓华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意公司在生产经 营中可能存在的政策及行业风险、药品带量采购风险、市场竞争加剧风险、 新产品研发风险等风险，有关风险因素内容与对策举措已在本报告中第三节 "管理层讨论与分析"之"十、公司面临的 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-33 河北常山生化药业股份有限公司（以下简称"公司"）第六届董事会第三次 会议于 2025 年 8 月 22 日在公司办公楼会议室召开。本次会议于 2025 年 8 月 12 日以邮件或直接送达的方式确保每一位董事收到本次会议通知。与会的各位董事 均已知悉与所议事项相关的必要信息。会议应参与表决董事 6 名，实际参与表决 董事 6 名。本次会议由公司董事长高晓东先生主持，符合《公司法》及《公司章 程》等规定。 会议以记名投票方式对各项议案进行表决，审议通过如下议案： 一、审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 公司《2025 年半年度报告》内容真实、准确、完整地反映了公司 2025 年半 年度的经营情况，不存在虚假记载、误导性陈述或者重大遗漏。具体内容详见公 司同日发布的《2025 年半年度报告》。 公司《2025 年半年度报告》中的财务报告已经公司董事会审计委员会审议 通过。 表决结果：6 票同意；0 票反对；0 票弃权。 二、审议通过《关于制定<信息披露暂缓与豁免管理制度>的议案》 表决结果：6 票同意；0 票反对；0 ...

Market Overview - On August 20, the A-share market saw a rebound with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index all reaching new highs for the year. The Shanghai and Shenzhen markets had a total trading volume of 2.41 trillion yuan, a decrease of 180.1 billion yuan from the previous trading day, marking six consecutive days of over 2 trillion yuan in trading volume. Over 3,600 stocks rose in the market [2][3] - The Shanghai Composite Index increased by 1.04% to 3766.21 points, the Shenzhen Component Index rose by 0.89% to 11926.74 points, and the ChiNext Index gained 0.23% to 2607.65 points [3] Sector Performance - Chip stocks surged in the afternoon, while consumer stocks such as liquor rebounded. Consumer electronics also showed active performance. Conversely, high-priced stocks collectively fell, with sectors like film, chemical pharmaceuticals, CRO, and vitamins experiencing declines. The top-performing sectors included liquor, semiconductors, AI glasses, and minor metals, while the worst-performing sectors were film, chemical pharmaceuticals, CRO, and vitamins [2] International Market - In the U.S. stock market on August 20, the Dow Jones Industrial Average rose by 16.04 points (0.04%) to 44938.31 points, while the S&P 500 fell by 15.59 points (0.24%) to 6395.78 points, and the Nasdaq Composite dropped by 142.09 points (0.67%) to 21172.86 points [4][6] - In Europe, the FTSE 100 index increased by 98.92 points (1.08%) to 9288.14 points, while the CAC 40 index in France fell by 6.05 points (0.08%) to 7973.03 points, and the DAX index in Germany decreased by 146.10 points (0.60%) to 24276.97 points [4] Commodity Prices - International oil prices rose on August 20, with light crude oil futures for September delivery increasing by $0.86 (1.38%) to $63.21 per barrel, and Brent crude oil futures for October delivery rising by $1.05 (1.60%) to $66.84 per barrel [5] Automotive Market - According to the China Passenger Car Association, from August 1 to 17, the national retail sales of passenger cars reached 866,000 units, a year-on-year increase of 2%. Cumulatively, retail sales for the year reached 13.611 million units, up 10% year-on-year. The retail sales of new energy vehicles during the same period were 502,000 units, a year-on-year increase of 9% [11] Financial Regulations - The National Financial Regulatory Administration has proposed that the proportion of controlling mergers and acquisitions loans should not exceed 70% of the transaction price, while equity funds must account for at least 30%. This aims to mitigate high-leverage merger financing risks [8] Company Announcements - Muyuan Foods reported a net profit growth of 1170% year-on-year for the first half of the year, while Weicai Technology saw a net profit increase of 831% year-on-year. Tianwei Foods is planning to issue H-shares and list on the Hong Kong Stock Exchange [14]

（编辑 任世碧） 证券日报网讯 8月19日晚间，常山药业发布公告称，截至本公告披露日，公司及子公司不存在为合并报 表以外单位提供担保，也不存在逾期担保、涉及诉讼的担保及因担保被判决败诉而应承担的损失等情 形。 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-32 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）借款 融资提供不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起 至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供 担保额度预计的公告》（公告编号：2025-14）。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、被担保人基本情况 1．企业名称：河北常山凯库得生物技术有限公司 2．企业类型：有限责任公司 3．注册地址：中国（河北）自由贸易试验区正定片区正定县高新技术产业 开发区北区赵普大街 19 号 4．成立日期：2018 年 02 月 06 日 5 ...

Core Insights - The market for weight loss drugs is gaining significant attention, with companies like Silverno Pharmaceuticals and others experiencing substantial stock price increases [1][5][11] - Silverno Pharmaceuticals has seen a remarkable IPO performance, with a 5341.66 times oversubscription and a market capitalization exceeding HKD 26 billion [3] - The overall performance of weight loss-related stocks in both Hong Kong and A-share markets has been strong, with several companies reporting over 100% gains this year [5][8] Company Performance - Silverno Pharmaceuticals' core product, Isupaglutide α, has generated revenue of approximately CNY 38.14 million within four months of its launch in China [3] - Other companies like Pag Biopharma and Songli Pharmaceutical have also seen significant stock price increases, with Pag Biopharma rising 32.45% and Songli Pharmaceutical increasing by 13.72% [4][5] - In the A-share market, companies such as Borui Pharmaceutical and Changshan Pharmaceutical have reported gains of 280% and over 100%, respectively [8][10] Market Trends - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [5] - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, highlighting the potential for domestic oral weight loss drugs [11] - Companies with strong research and sales capabilities are expected to dominate the commercialization of weight loss drugs, with a focus on those with advanced R&D progress [11]

Group 1 - The core viewpoint of the articles highlights a significant rise in the innovative drug sector, driven by the establishment of a new pricing mechanism for newly launched drugs by the National Medical Insurance Administration [1][2] - The new pricing mechanism is expected to provide higher pricing flexibility, more efficient listing processes, and longer price stability periods for high-quality innovative drugs [1] - Companies in the innovative drug sector, such as Shouyao Holdings and Microchip Biotech, have seen substantial stock price increases, indicating positive market sentiment towards the sector [1] Group 2 - Since 2025, the government has repeatedly proposed policies to optimize drug procurement and support innovative drugs, indicating a favorable policy environment for the development of innovative drugs [2] - The investment strategy for the second half of 2025 suggests a high certainty of performance and valuation recovery in the healthcare industry, driven by external factors such as policy optimization and the rise of commercial health insurance [2] - The trend towards self-sufficiency and the reform of out-of-hospital marketing models are seen as more certain investment directions in the context of true innovation and internationalization in the pharmaceutical sector [2]

常山药业8月11日披露，截至8月10日公司股东户数为55333户，较上期（7月31日）减少3187户，环比降 幅为5.45%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （原标题：常山药业最新股东户数环比下降5.45% 筹码趋向集中） ...

Group 1 - The company is currently focused on completing the drug review response work and is working overtime to prepare supplementary materials, but cannot determine the exact response time [2] - The company is developing two anti-tumor targeted original new drugs, CSCJC3456 and CSCJC4523 [2] - There is a strong expectation from patients for the drugs to be approved and to contribute to public health, raising questions about the company's ability to meet market demand post-approval [2]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]